MapLight Therapeutics, Inc. Shareholders' Equity
MapLight Therapeutics, Inc. (MPLT) had Shareholders' Equity of $348.30 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $348.30M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $399.83M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $458.37M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$274.18M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $348.30M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $399.83M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $458.37M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$274.18M 10-Q · filed 2025-12-04 | |
| 2025-06-30 | -$245.06M 10-Q · filed 2026-08-13 | -$245.06M 10-Q · filed 2025-12-04 |
| 2025-03-31 | -$215.83M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | -$193.63M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | -$172.37M 10-Q · filed 2025-12-04 | |
| 2024-06-30 | -$154.33M 10-Q · filed 2025-12-04 | |
| 2024-03-31 | -$136.00M 10-Q · filed 2025-12-04 | |
| 2023-12-31 | -$117.58M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |